lorvotuzumab mertansine + carboplatin + etoposide

A combination regimen of **lorvotuzumab mertansine** (an antibody-drug conjugate targeting CD56-expressing cells, comprising the humanized anti-CD56 antibody lorvotuzumab conjugated to the microtubule inhibitor DM1 via a cleavable disulfide linker), **carboplatin** (a platinum-based DNA crosslinking agent), and **etoposide** (a topoisomerase II inhibitor). Lorvotuzumab mertansine binds CD56 (neural cell adhesion molecule 1) on tumor cells, is internalized, and releases DM1 intracellularly, disrupting microtubules and causing apoptosis; it may also mediate antibody-dependent cytotoxicity. Carboplatin forms DNA adducts resulting in cell death, while etoposide inhibits DNA re-ligation by topoisomerase II, causing double-strand breaks. This combination has been investigated in preclinical and early clinical settings for CD56-positive tumors such as small cell lung cancer, neuroendocrine tumors, and other CD56-expressing malignancies. The intent is to target tumors with high CD56 expression with the ADC while using established cytotoxic chemotherapy to enhance antitumor efficacy[1][2][4].

Other names

lorvotuzumab mertansine + carboplatin + etoposide